FibroBiologics, Inc. – What You Need to Know

Thinking about investing in FibroBiologics? Biotech investing is like a rollercoaster. Here is a plain-English breakdown of what you need to know before you put your money on the table.

1. What does this company do?

FibroBiologics aims to "reprogram" how we treat chronic diseases. Instead of just managing symptoms with pills, they focus on fibroblast cells—the most common cells in your connective tissue. They are developing technology to turn these cells into treatments for wound healing, multiple sclerosis, and back pain.

The company is a clinical-stage biotech firm. Their business model relies entirely on research. They have no approved drugs and generate no profit from product sales. They are currently burning cash to fund laboratory work and clinical trials without a steady stream of income to cover these costs.

2. What’s happening right now? (The April 2026 Offering)

The company is raising money by selling "units" to investors. Here is the breakdown:

• The Deal: Each unit includes one share of stock and a "warrant." A warrant is a coupon that lets you buy more stock later at $1.32. These are usable immediately and expire in five years.
• The "Best Efforts" Risk: The placement agent does not have to sell a specific number of units. If interest is low, the company may raise much less money than planned, leaving them underfunded.
• No Safety Net: There is no escrow account. The company gets your money immediately. If the research fails or they run out of cash, you will not get your money back.
• The Reverse Split: On March 30, 2026, the company performed a 1-for-20 reverse stock split. If you owned 20 shares before, you now own one. This was done to keep the stock price high enough to stay listed on the Nasdaq.
• Dilution: When you buy in, your "slice of the pie" is immediately smaller than the price you paid. Because the company has many outstanding warrants and options, your ownership percentage will likely shrink further if those are used.

3. Who is in charge?

Founder and CEO Pete O’Heeron holds Series C Preferred Stock.

• Super-Voting Power: While regular investors get one vote per share, these shares carry 13,000 votes each.
• The Proxy: While the CEO lets the board vote these shares, this structure ensures leadership keeps control over all major decisions. Common shareholders have almost no influence over the company’s direction or board elections.

4. What are the main risks?

• "Penny Stock" Status: If the company fails to meet Nasdaq requirements, the stock could be delisted. This makes it harder to sell your shares and increases price swings.
• No Dividends: The company has never paid a dividend and does not plan to. They intend to use all available cash to fund their business.
• Broad Discretion: Management can spend the money from this offering however they choose. They are not required to follow their original spending plan or ask for your approval to change it.
• Financial Viability: The company has a history of losses. They rely on raising money from investors to stay in business because they do not make enough money from their operations.

5. How to think about this investment

If you are considering this, ask yourself: "Am I comfortable with the possibility of this company failing?"

Because this is a pre-revenue biotech company, there is no guarantee their science will ever turn into a profitable product. The company didn't provide much detail in their filing regarding specific timelines for when they expect to be self-sustaining, so you should assume this is a long-term, high-risk bet on scientific success rather than a short-term trade.

A final word: Only invest money you are comfortable losing. This is a speculative play, not a "get rich quick" scheme.

Disclaimer: I am an AI, not a financial advisor. This guide is for informational purposes only. Always do your own research and read the official SEC filings before making any investment decisions.